Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Genelux CorporationNASDAQ: GNLX

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital growth accelerates

Q1 FY2026 other working capital of $677K (cash outflow) rose 14.4% year over year, ahead of the -92.3% change in trailing-twelve-month other working capital.

Context

  • Other working capital amounted to 2087.5% of revenue in FY2025, down 15475.0 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +14.4% holds above the trailing-twelve-month pace of -92.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$677K-205.6% QoQ
Last fiscal yearDec 2025
$167K+111.9% YoY
LTMMar 2026
$82K-92.3% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.4%——
1 year+111.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
167K USD
Year-over-year change
+111.9%
4-year CAGR
-52.7%

Other Working Capital vs competitors

How GNLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -92.3% is the 6th highest of 9, against a peer median of -16.3%.
  • Other working capital amounts to 1025.0% of revenue for GNLX, versus a peer median of 149.2%.
GNLX Competitors
Other Working Capital for GNLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$12.21M USD+0.4%—17.9%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$12.15M USD+749.2%——
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$8.69M USD-1032.5%+70.8%—
SLNSilence Therapeutics plcLTM Mar 2026$8.34M USD——905.3%
ACIUAC Immune S.A.LTM Dec 2025CHF 5.33M CHF-105.7%-9.1%149.2%
LYELLyell Immunopharma, Inc.LTM Mar 2026$3.12M USD-33.0%-55.0%10071.0%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$1.95M USD———
CADLCandel Therapeutics, Inc.LTM Mar 2026$1.55M USD+2140.6%+2.7%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.01M USD-122.5%+26.3%—
MREOMereo BioPharma Group plcLTM Mar 2026$562.58K USD+511.5%—112.5%
GNLXGenelux CorporationLTM Mar 2026$82K USD-92.3%—1025.0%
Peer median (excluding GNLX) —-16.3%+2.7%149.2%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(16.38M)(5.21M)(28.3M)(29.87M)(32.15M)
Depreciation & Amortization895K968K1.02M903K244K
Deferred Income Tax348K0000
Stock-Based Compensation4.27M2.42M5.2M6.07M5.87M
Change in Working Capital4.08M(1.69M)(3.28M)751K(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables754K2.31M(2.36M)2.16M(1.21M)
Other Working Capital3.33M(4M)(923K)(1.41M)167K
Other Non-Cash Items196K(56K)5.08M917K1.81M
Operating Cash Flow(6.59M)(3.57M)(20.28M)(21.23M)(25.27M)
Capital Expenditures0(49K)(1.03M)(381K)(1.1M)
Acquisitions (Net)00000
Purchases of Investments00(13.7M)(29M)(18.26M)
Sales of Investments00021.25M31.5M
Other Investing Activities00000
Investing Cash Flow0(49K)(14.72M)(8.13M)12.14M
Debt Repayment(558K)970K215K00
Common Stock Issued143K120K39.65M27.82M9.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities145K(1.45M)4.16M688K0
Financing Cash Flow(270K)(478K)44.02M28.51M9.9M
Effect of Forex Changes00000
Net Change in Cash(6.86M)(4.1M)9.02M(853K)(3.23M)
Free Cash Flow(6.59M)(3.62M)(21.3M)(21.61M)(26.37M)

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.